Critically evaluate the role of pharmacopoeial standardisation in mainstreaming AYUSH systems within India's public health framework.

Pharmacopoeial standardisation fixes uniform identity, purity and quality parameters for drugs through official monographs. For AYUSH — whose acceptance in public health has long been contested on grounds of evidence — such standardisation is the bridge between traditional knowledge and regulatory science, as seen in the PCIM&H–Indian Pharmacopoeia Commission "One Herb, One Standard" initiative [1][2].

Merits: enabling mainstreaming

• Ends regulatory divergence: the same herb earlier carried different standards in the ASU&H pharmacopoeias and the Indian Pharmacopoeia; harmonised monographs give one benchmark across systems [1].
• Inter-ministerial convergence: the Ayush and Health ministries jointly develop technical content while PCIM&H retains publication authority — a workable model against departmental silos [1].
• Regulatory enforceability: standards in the Ayurvedic, Siddha, Unani and Homoeopathic Pharmacopoeias of India operate as mandatory statutory standards, not advisory guidance [3].
• Trade and credibility: uniform quality supports export competitiveness and India's positioning of traditional medicine on global platforms [4].
• Demonstrated output: 50 medicinal-plant monographs in the first phase, with the framework renewed in 2026 for a further three years [2].

Limits: why standardisation alone is insufficient

• Coverage gap: a few dozen monographs against thousands of medicinal plants in use leaves much of the market unstandardised [2].
• Soft-law architecture: progress rests on a renewable MoU rather than statutory mandate, making continuity dependent on administrative will [1][2].
• Standardisation ≠ efficacy: monographs certify raw-material quality, not clinical outcomes; mainstreaming also needs trials, pharmacovigilance and prescriber integration.
• Last-mile enforcement: benefits depend on testing laboratories, trained analysts and inspection capacity at the state level.
• Epistemic tension: classical formulations resting on individualised practice do not always map neatly onto uniform chemical markers.

On balance, pharmacopoeial standardisation is a necessary and quietly transformative first step — it makes AYUSH legible to regulators, insurers and export markets. Its promise will be realised if the monograph base is widened, backed by statutory footing, testing infrastructure and clinical evidence, so that AYUSH advances India's goal of universal health coverage on the strength of demonstrated quality.